- Home
- CWAN vs LNTH Comparison
CWAN vs LNTH Comparison
Compare CWAN & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CWAN | LNTH |
|---|---|---|
| Founded | 2004 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.2B |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CWAN | LNTH |
|---|---|---|
| Price | $21.77 | $66.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $30.67 | ★ $77.33 |
| AVG Volume (30 Days) | ★ 6.4M | 1.0M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46826.67 | N/A |
| EPS | 1.40 | ★ 2.39 |
| Revenue | $640,376,000.00 | ★ $1,525,933,000.00 |
| Revenue This Year | $64.92 | $0.01 |
| Revenue Next Year | $29.34 | $1.24 |
| P/E Ratio | ★ $15.57 | $27.84 |
| Revenue Growth | ★ 50.91 | 1.95 |
| 52 Week Low | $15.74 | $47.25 |
| 52 Week High | $32.00 | $111.29 |
Technical Indicators
Market Signals| Indicator | CWAN | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 60.07 | 72.55 |
| Support Level | $20.85 | $60.15 |
| Resistance Level | $22.40 | $64.40 |
| Average True Range (ATR) | 0.68 | 2.09 |
| MACD | -0.06 | 0.66 |
| Stochastic Oscillator | 59.03 | 94.44 |
Price Performance
Historical ComparisonAbout CWAN Clearwater Analytics Holdings Inc.
Clearwater Analytics describes its mission as aiming to be the world's most trusted and comprehensive technology platform for the entire investment cycle. Clearwater has historically focused on back-office functions such as investment accounting, but with acquisitions such Enfusion, Beacon, and Bistro, the firm has broadened its focus with front-office and middle-office capabilities. Clearwater primarily serves insurance companies, asset managers, hedge funds, and corporate treasuries. Pro forma for Enfusion, about 76% of Clearwater's revenue is generated in the US.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.